The Quantellect read.As of Nov 19, 2026, 8 active firms cover CytomX Therapeutics Inc: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $12.63 sits 570% above the current $1.89. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.63
+569.8% upside
Average target across 8 active firms as of Nov 19, 2026 vs $1.89 current
Highest Target$16.00
Average Target$12.63
Lowest Target$10.00
Detailed analyst forecasts for CTMX
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate CTMX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CTMX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.13 – $-0.05 · 5 analysts · +2% YoY
Next period, 5 analysts expect CytomX Therapeutics Inc to earn $-0.10 a share (range $-0.13 – $-0.05), versus $-0.10 a year earlier. Full-year consensus is $-0.39, growing to $-0.50 the year after.
REVENUE · NEXT QUARTER
$5.1M
Range $0 – $10.3M · 5 analysts · -51% YoY
Revenue is expected to reach $5.1M (range $0 – $10.3M), -50.5% year-over-year. Full-year consensus is $22.0M, rising to $26.1M next year.
Top analysts covering CytomX Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTMX.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$14.00+642.7% to target
Overall win rate
53%
+ Follow
#2
Roger Song
Jefferies · Rank #122
Buy
$16.00+748.8% to target
Overall win rate
43%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Buy
$11.00+483.6% to target
Overall win rate
48%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$11.00+483.6% to target
Overall win rate
33%
+ Follow
#5
Joseph Catanzaro
Piper Sandler · Rank #353
Buy
$12.00+536.6% to target
Overall win rate
41%
+ Follow
CTMX stock forecast FAQ
What is CTMX's average 12-month price target?+
The 8 active firms with a live target average $12.63 for CytomX Therapeutics Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low, as of Nov 19, 2026.
Is CTMX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CTMX?+
The Street-high target is $16.00 (Barclays), and the Street-low is $10.00 (Cantor Fitzgerald). The average of all 8 active-firm targets is $12.63.
How many active Wall Street firms cover CTMX?+
8 active firms have a recognized rating on CytomX Therapeutics Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CTMX?+
Among analysts who currently cover CTMX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $14.00 target.
What is CytomX Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.13 – $-0.05) across 5 analysts. Full-year EPS is projected at $-0.39, rising to $-0.50 the following year.
How much revenue is CytomX Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.1M (range $0 – $10.3M). Full-year revenue is projected at $22.0M, growing to $26.1M next year.
Have analysts been upgrading or downgrading CTMX lately?+
As of Nov 19, 2026, 8 of 8 active firms rate CTMX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTMX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.